Digestive System Neoplasms clinical trials

The registry lists 195 studies for Digestive System Neoplasms across more than 10 countries. 57 are recruiting or about to start. 56 of them are mainly about Digestive System Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 37 narrower conditions too, such as Colorectal Neoplasms: 23,498 studies, 6,447 open.

Get an email when these change. Save the Digestive System Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 76
Recruiting: 52
Status unknown: 28
Terminated: 21
Active, not recruiting: 11
Not yet recruiting: 5

Phase

Phase 2: 63
Phase 1: 52
Phase 3: 20
Early Phase 1: 3
Phase 4: 2

Where

China: 75
United States: 63
France: 31
Spain: 18
Canada: 16
Germany: 16

Who runs them

Sichuan Baili Pharmaceutical Co., Ltd. (8) · Exact Sciences Corporation (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Sumitomo Pharma America, Inc. (4) · Pfizer (4) · Shenzhen Hornetcorn Bio-technology Company, LTD (4) · Fudan University (4) · Royal Marsden NHS Foundation Trust (3)

What is being tested here

Drugs under test in Digestive System Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Irinotecan	1	2	3
Camrelizumab	1	0	2
L-(+)-methylenetetrahydrofolic acid	1	0	2
Bevacizumab	1	2	2
Imatinib	1	0	2
GNC-077	1	0	1
SKB571	1	0	1
BL-M08D1	1	0	1
Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404	1	1	1
SI-B036	1	0	1

Drug classes tested here Immune checkpoint inhibitors 4 open · Tyrosine kinase inhibitors (TKIs) 3 open · Angiogenesis inhibitors 1 open · Antimetabolites 7 · Antimitotic agents 7

Coming up

6phase 3 studies under way

25studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC · Phase 3 · Sun Yat-sen University
Nov 2026Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients · Jiangxi Provincial Cancer Hospital
Dec 2026A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor · Sichuan Baili Pharmaceutical Co., Ltd.
Dec 2026The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer · The First Hospital of Jilin University
Dec 2026KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade · Peking University Cancer Hospital & Institute
Dec 2026Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations · Assistance Publique - Hôpitaux de Paris
Dec 2026Determining Minimal Residual Disease Using ctDNA Deep Sequencing · Masaryk Memorial Cancer Institute
Dec 2026The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors · Huashan Hospital
Mar 2027A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) · Eisai Co., Ltd.
Apr 2027EUS-guided RFA for Solid Abdominal Neoplasms · Chinese University of Hong Kong

Who these studies take

Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger. 2 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (2%) take healthy volunteers.

Recruiting studies that take each age, of 52
Age	Women	Men
10	1 (2%)	1 (2%)
18	49 (94%)	49 (94%)
30	50 (96%)	50 (96%)
40	51 (98%)	51 (98%)
50	52 (100%)	52 (100%)
65	52 (100%)	52 (100%)
75	49 (94%)	49 (94%)
85	31 (60%)	31 (60%)

Across all 195 studies, recruiting or not: 20% stop at 75 or younger and 2% at 65; 3% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Digestive System Neoplasms studies take

Of 29 phase 2 interventional studies under Digestive System Neoplasms, half reached primary completion within 44 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	44 mo33–61 · 29 studies	—	—
Interventional, no phase	20 mo15–… · 24 studies	—	—
Observational	36 mo14–102 · 24 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsOct 13, 2026NCT07780318

Newly registered1

Evaluation of Preoperative Anxiety in Digestive SurgeryOct 27, 2026NCT07897942

Studies

Recruiting first, then most recently updated. Showing 50 of 195. Browse all 195 → or search them.